Amgen Inc. and Takeda Pharmaceutical Company Limited

Amgen Inc. and Takeda Pharmaceutical Company Limited have entered into an agreement under which Takeda will develop and commercialize for the Japanese market up to 13 molecules from Amgen's pipeline, one of which is included as an option. The collaboration includes early to mid-stage clinical-stage candidates across a range of therapeutic areas, including oncology, inflammation, and pain. The financial terms include an upfront cash payment to Amgen of $200 million. Takeda will also pay to Amgen up to $340 million in expected worldwide development costs for these molecules over the next several years, $362 million in success-based milestone payments, and double digit royalties on sales in Japan. In addition, Takeda will become Amgen's worldwide partner for motesanib diphosphate (AMG 706), and will pay Amgen $100 million upfront, $175 million in success-based milestones for the first two indications, and double digit royalties on sales in Japan. Takeda will also pay 60% of ongoing clinical development expenses outside Japan and share potential profits outside Japan 50/50.